QIAGEN N.V. (NYSE:QGEN) recently announced the launch of two products for providing valuable insights on several types of blood cancer. The company will be showcasing the launches at the American Society of Hematology 2018 Annual Meeting and Exposition in San Diego.
The company’s latest offering, QIAact Myeloid DNA UMI Panel for the GeneReader NGS System, aims at delivering an integrated Sample to Insight workflow targeting the genes and variants of most relevance to onco-hematology research. Furthermore, the QIAact Myeloidpanel covers 25 highly relevant genes along with their variants.Notably, the panel will be made available for research in December 2018.
QIAGEN has also launched a web-based clinical decision support platform for the QIAGEN Clinical Insight (QCI) Interpret bioinformatics solution for hematological malignancies, including leukemia, Non-Hodgkin lymphoma, Hodgkin lymphoma and multiple myeloma.
Progress With Test Menu Expansion
QIAGEN is progressing well with its testing menu expansion strategy. It recently launched its next-generation multiplex gastrointestinal panel — QIAstat-Dx — in Europe. The QIAstat-Dx system along with the gastrointestinal and respiratory panels was recently registered and launched in Australia. QIAGEN expects to receive FDA approval for QIAstat-Dx and both the panels in 2019.
The company also plans to launch a CE-In Vitro Diagnostics (IVD) marked QIAstat-Dx multiplex test for meningitis in 2019. Moreover, a wide range of assays for syndromic testing in oncology and other therapeutic areas are currently in the pipeline.
The company also announced the clearance of PMA Supplement for broadening the use of therascreen EGFR RGQ PCR Kit as a companion diagnostic with Pfizer Inc (NYSE:PFE).’s VIZIMPRO (dacomitinib) by the FDA.
QIAGEN also announced a new development under its long-standing partnership with IVD player DiaSorin S.p.A. This time, the alliance is set to offer a fully-automated CE-Marked testing for latent tuberculosis (TB) infection with QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) on DiaSorin LIAISON platforms.
Share Price Performance
QIAGEN has been gaining investor confidence on consistently encouraging results. Over the past year, the company’s share price has outperformed its industry. The stock has gained 10.7% against the industry’s 14.7% fall.
Zacks Rank & Key Picks
QIAGEN currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Integer Holdings Corporation (NYSE:ITGR) , Surmodics, Inc. (NASDAQ:SRDX) and Veeva Systems (NYSE:VEEV) .
Integer Holdings has an earnings growth rate of 31.2% for the next quarter and a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Surmodics’ long-term earnings growth rate is projected at 10%. The stock carries a Zacks Rank of 2.
Veeva Systems’ long-term earnings growth rate is estimated at 19.3%. The stock carries a Zacks Rank #2.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Veeva Systems Inc. (VEEV): Free Stock Analysis Report
Integer Holdings Corporation (ITGR): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
QIAGEN N.V. (QGEN): Free Stock Analysis Report
Original post